Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30244% above fair value
$116.35+4.35 (+3.88%)
Close on Nov 18, 2026Market cap $7.30BP/E –Yield –
Twist Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Twist Bioscience's free cash flow for the twelve months ending Jun 30, 2026 was -$93.12M. For fiscal 2025 it was -$75.63M. The highest annual figure on record is -$57.90M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$75.63M | – |
| FY2024 | Sep 30, 2024 | -$69.17M | – |
| FY2023 | Sep 30, 2023 | -$170.25M | – |
| FY2022 | Sep 30, 2022 | -$226.24M | – |
| FY2021 | Sep 30, 2021 | -$139.31M | – |
| FY2020 | Sep 30, 2020 | -$152.12M | – |
| FY2019 | Sep 30, 2019 | -$102.69M | – |
| FY2018 | Sep 30, 2018 | -$69.85M | – |
| FY2017 | Sep 30, 2017 | -$57.90M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$8.65M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$25.45M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$34.79M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$24.24M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$10.57M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$17.13M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$23.70M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$17.32M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$7.34M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$20.03M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$24.48M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$23.10M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$27.92M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$53.34M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$65.89M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$17.73M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$74.77M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$74.31M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$59.44M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$42.89M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$34.90M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$32.95M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$28.56M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$27.43M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$26.32M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$61.41M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$36.97M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$27.25M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$27.25M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$24.58M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$23.61M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$17.74M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$17.57M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$17.01M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$17.53M | – |
See a number that looks wrong?